bioecon Member area
Technology · Health & biomedicine / Therapeutics & platforms

Selective Organ Targeting (SORT) Lipid Nanoparticles for Extrahepatic mRNA Delivery

Incorporating systematic charged or zwitterionic SORT lipids into ionizable LNPs to engineer tissue biodistribution away from the liver directly to lungs, spleen, and bone marrow in vivo.

Medicine & Pharmaceuticals Maturity 6/9 Risk: medium Pharma & biologics Advanced therapies US · EU · CN verified 2026-11-15 · 3 Sources (1 independent)

1 · What it gives

Selective Organ Targeting (SORT) Lipid Nanoparticles for Extrahepatic mRNA Delivery represents an advanced frontier in nucleic acid therapeutics, enabling sequence-specific regulation of target transcript expression without modifying the underlying genomic sequence. By addressing historical barriers of rapid enzymatic nuclease degradation, minimal membrane permeability, and off-target immunostimulation, the platform establishes robust industrial synthesis and formulation pipelines. Chemically stabilized nucleotide building blocks and targeted bioconjugates bypass empirical discovery cycles, delivering predictable, reproducible, and scalable therapeutic candidates.

The technological spectrum spans automated solid-phase phosphoramidite synthesis, high-efficiency duplex annealing, and targeted endosomal release mechanics. High-density columns and flow-through synthesizers achieve step-wise coupling efficiencies exceeding 99.2%, while orthogonal purification cascades isolate full-length oligomers at >98.5% purity. Analytical release protocols integrate high-resolution Orbitrap mass spectrometry, capillary gel electrophoresis, and cell-based target mRNA knockdown assays, ensuring stringent control over stereochemical purity and impurity profiles.

The key directions of this technology are:

  1. Chemical Backbone Stabilization in Selective Organ Targeting (SORT) Lipid Nanoparticles for Extrahepatic mRNA Delivery: Implementing comprehensive 2’-O-methyl (2’-OMe), 2’-fluoro (2’-F), and stereopure phosphorothioate modifications to prevent serum endonucleolytic degradation.
  2. Tissue-Specific Ligand Conjugation: Direct covalent coupling of branched triantennary targeting ligands, receptor-binding peptides, or lipid anchors to achieve organ-selective biodistribution.
  3. Preparative Chromatography & Desalting: Optimizing strong anion-exchange (SAX) and ion-pair reversed-phase (IP-RP) HPLC for baseline separation of full-length sequences from n-1 deletion impurities.
  4. Closed Aseptic Fill-Finish Operations: Formulating high-concentration, low-viscosity aqueous drug substance batches under Class A isolators for sterile pre-filled syringe (PFS) delivery.

Sectoral value chain#

┌────────────────────────────────────────────────────────┐
│  Tier 1: Phosphoramidite & Monomer Raw Material Prep   │
│  (High-purity nucleosides, 2'-modified amidites)       │
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 2: Automated Solid-Phase Oligo Synthesis (SPOS)  │
│  (Controlled Pore Glass, coupling efficiency >99.2%)   │
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 3: Cleavage, Deprotection & Anion Exchange HPLC  │
│  (Aqueous ammonolysis, SAX chromatography polishing)   │
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 4: Duplex Annealing & Tangential Flow Filtration │
│  (Equimolar pairing, UF/DF desalting, 3-5 kDa cutoff)  │
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 5: Aseptic Formulation & Sterile PFS Packaging   │
│  (0.22 um sterile PES filtration, USP <788> testing)   │
└────────────────────────────────────────────────────────┘

Value chain levels#

LevelDescriptionKey inputs/outputs
Monomer & Synthon SynthesisPrecision chemical synthesis and quality control of 2’-modified ribonucleoside phosphoramidites.In: Nucleoside bases, phosphitylating reagents, solid supports.
Out: HPLC-certified phosphoramidites with purity >99.0%.
Solid-Phase Column AssemblyStepwise automated chain elongation via cyclical deblocking, coupling, oxidation/sulfurization, and capping.In: Phosphoramidites, activators, sulfurizing reagents, CPG.
Out: Fully assembled protected oligomer bound to solid matrix.
Cleavage & Chromatographic PolishingAqueous ammonolysis to release chains and deprotect exocyclic amines, followed by preparative SAX-HPLC.In: Ammonia/methylamine solutions, sodium perchlorate buffers.
Out: Purified single-stranded or conjugated oligonucleotide pools.
Duplex Annealing & Membrane DesaltingControlled stoichiometric thermal hybridization and ultrafiltration/diafiltration (UF/DF) for salt removal.In: Single strands, pure WFI, 3 kDa PES membrane cassettes.
Out: High-purity duplex oligonucleotide bulk active substance.
Sterile Fill-Finish & PackagingCompounding in isotonic buffer, terminal 0.22 um membrane filtration, and automated syringe filling.In: Purified drug substance, sterile buffer, glass syringes.
Out: Final sterile injectable product released under cGMP.

Cross-cutting technologies of the sector:

  • Process Analytical Technology (PAT): Real-time UV-Vis trityl monitoring and in-line conductivity sensors ensuring closed-loop coupling feedback.
  • Orbitrap High-Resolution LC-MS: Intact mass verification and sequence profiling identifying trace truncation and failure sequences.

2 · What it replaces 0 · matched by industry

No graded substitution linked yet.

3 · How to implement 4 steps

  1. 1
    SORT lipid biophysical tailoring
    Selecting specific molar ratios of cationic (DOTAP) for lung or anionic (18:1 BMP) for spleen targeting.
  2. 2
    Microfluidic hydrodynamic mixingFormulation & blending
    Rapid chaotic mixing of ethanol lipid stream with aqueous mRNA buffer forming 80 nm particles.
  3. 3
    Serum protein corona remodeling
    SORT lipids reprogram the endogenous apolipoprotein corona, preventing ApoE-dependent hepatic uptake.
  4. 4
    Target organ endocytosis
    Direct intracellular delivery of mRNA payloads into pulmonary epithelial cells or splenic lymphocytes.

4 · Who delivers

Matched suppliers (matched automatically)

Accra Compost and Recycling Plant LimitedGhanaProduceractive
NaturmegaColombiaProduceractive
BrevelIsraelProduceractive
HolifermUnited KingdomResearch / RTOactive
CheckerspotUnited StatesProduceractive
Lonza GroupSwitzerlandProduceractive
United TherapeuticsUnited StatesProduceractive
GSKUnited KingdomProduceractive

Leading companies and institutes (from the brief)

Company / InstituteCountryKey products / platformsTech featuresStatus 2026
Recode🇺🇸 United StatesSpecialized Modality & Process PlatformIndustrial scalable manufacturing & QbD validationcommercial
Ut🇺🇸 United StatesSpecialized Modality & Process PlatformIndustrial scalable manufacturing & QbD validationcommercial
Recode Therapeutics🇺🇸 United StatesProprietary Therapeutics & Process InfrastructureIndustrial scalable manufacturing & QbD validationclinical
Innorna🇺🇸 United StatesProprietary Therapeutics & Process InfrastructureIndustrial scalable manufacturing & QbD validationclinical
Axelyf🇺🇸 United StatesProprietary Therapeutics & Process InfrastructureIndustrial scalable manufacturing & QbD validationclinical
Hopewell Therapeutics, .🇺🇸 United StatesProprietary Therapeutics & Process InfrastructureIndustrial scalable manufacturing & QbD validationclinical
Lonza Group🇨🇭 SwitzerlandCustom Biologics CDMO & Ibex SolutionsIndustrial scalable manufacturing & QbD validationcommercial

5 · Rules & route to market

United States

FDA CDER approval pathways, venture backing, and CDMO capacity#

  • FDA Regulatory Framework: Clinical advancement under CDER and CBER 505(b)(1) NDA pathways, supported by established FDA guidances on oligonucleotide drug substance quality.
  • Manufacturing Infrastructure: Large-scale automated solid-phase synthesis facilities in Massachusetts and North Carolina supporting commercial-scale oligonucleotide production.
  • Translational Pipelines: Active venture capital and NIH translational grant funding driving expanded clinical indications from rare genetic disorders to broad cardiovascular disease.

European Union

EMA PRIME designations, Swiss CDMO excellence, green chemistry#

  • European CDMO Dominance: Global contract development leaders (Lonza, Bachem, CordenPharma) scaling multi-kilogram to multi-ton oligonucleotide production suites.
  • EMA Centralized Authorizations: Harmonized regulatory pathways across EU member states with standardized post-approval safety monitoring protocols.
  • Green Solvent Innovations: Consortia developing bio-based green solvents (such as 2-MeTHF) to replace hazardous dimethylformamide in solid-phase synthesis.

China

National Key Bioeconomy Plans, CDE priority review, regional hubs#

  • NMPA Priority Review Status: China’s Center for Drug Evaluation (CDE) granting expedited pathways for innovative 用于肝外精准mRNA靶向递送的选择性器官靶向 (SORT) 脂质纳米颗粒 candidates targeting chronic viral hepatitis and metabolic disorders.
  • Suzhou & Shanghai Industrial Clusters: High-density biopharmaceutical ecosystems across Suzhou BioBAY and Zhangjiang providing localized monomer supplies and rapid CDMO scale-up.
  • Five-Year Plan Strategic Support: Direct prioritization under national biomanufacturing blueprints fostering domestic substitution of high-end synthesis reagents and automated synthesizers.

6 · Money: tenders & grants

No open tender or grant matched right now.

7 · Tech stack & innovations

  1. Engineered Molecular Backbone in Selective Organ Targeting (SORT) Lipid Nanoparticles for Extrahepatic mRNA Delivery:
    • Tailored 2’-OMe and 2’-F ribose modifications combined with terminal phosphorothioate linkages.
    • Provides sub-nanomolar target binding avidity while conferring complete resistance to serum exonucleases.
  2. Automated High-Throughput Synthesizers:
    • Dynamic axial compression columns operating up to 100 bar, ensuring uniform fluid distribution across polymer resin beds.
    • In-line PAT sensors delivering closed-loop automated feedback on coupling kinetics and washing cycles.
  3. Preparative Strong Anion-Exchange (SAX) HPLC:
    • High-resolution resin matrices delivering baseline chromatographic resolution between n and n-1 failure sequences.
    • Automated peak-fraction collection coupled with real-time UV and mass-selective detectors.

Sources 3 · 1 independent · 2 producer sites

Independent sources 1

  1. doi.org · doi.org research checked 2026-11-15

Producers' own sites 2

  1. Recode therapeutics producer checked 2026-11-15 · link not kept
  2. Ut southwestern siegwart lab producer checked 2026-11-15 · link not kept